3.44
0.19 (5.85%)
| Previous Close | 3.25 |
| Open | 3.25 |
| Volume | 792,970 |
| Avg. Volume (3M) | 613,222 |
| Market Cap | 300,782,208 |
| Price / Sales | 0.730 |
| Price / Book | 19.67 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2026 |
| Profit Margin | 46.54% |
| Operating Margin (TTM) | -32.78% |
| Diluted EPS (TTM) | 2.11 |
| Total Debt/Equity (MRQ) | 340.14% |
| Current Ratio (MRQ) | 3.70 |
| Operating Cash Flow (TTM) | -109.67 M |
| Levered Free Cash Flow (TTM) | -78.01 M |
| Return on Assets (TTM) | -58.61% |
| Return on Equity (TTM) | 121.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | X4 Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.43% |
| % Held by Institutions | 55.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Saturn V Capital Management Lp | 31 Dec 2025 | 5,800,530 |
| Kalehua Capital Management Llc | 31 Dec 2025 | 3,722,840 |
| Braidwell Lp | 31 Dec 2025 | 3,368,904 |
| Trails Edge Capital Partners, Lp | 31 Dec 2025 | 2,571,478 |
| 52 Weeks Range | ||
| Median | 10.00 (190.70%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 05 Dec 2025 | 10.00 (190.70%) | Buy | 3.98 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 |
| 02 Feb 2026 | Announcement | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |